Which Country Treats Cancer Better? (As of 2026)

There is no single correct answer to "which country treats cancer better" — national survival rates are simply country-level statistics that vary depending on cancer type and screening systems.

Key Takeaways

• There is no single answer to "which country treats cancer best," and national statistics are difficult to compare directly because cancer types, screening systems, and registration methods differ by country.
• Korea's 5-year relative survival rate for stomach cancer is 78.6%, while the US SEER-based stomach cancer survival rate is 39.8% (National Cancer Registration Statistics 2019–2023 / SEER 2016–2022), but much of this gap is explained by differences in early detection rates.
• Korea's 5-year relative survival rates are 94.7% for breast cancer, 75.6% for colorectal cancer, 40.4% for liver cancer, and 55.7% for leukemia — figures that vary widely by cancer type (National Cancer Registration Statistics 2019–2023).
• All survival rates are nationwide statistics for an entire country, not the performance of any specific hospital, and an individual's outcome depends on stage, subtype, age, and comorbidities.
• What actually matters is not a country's ranking but the treatment pathway suited to your own stage and subtype, which can be confirmed through remote review (pre-arrival review).

Why Is It Hard to Compare Survival Rates Across Countries?

• National statistics differ in registration systems, the age screening begins, and early detection rates, so a single number cannot tell you "which country is better."
• For example, in stomach cancer, Korea conducts a national screening program with gastroscopy every two years starting at age 40, which leads to a relatively high proportion of early-stage stomach cancer diagnoses — explaining much of the survival rate gap (National Cancer Registration Statistics 2019–2023).
• Colorectal cancer follows a similar pattern: Korea performs an annual national fecal occult blood test starting at age 50, followed by colonoscopy if positive, resulting in a relatively high detection rate at the polyp stage or early cancer stage (Colorectal Cancer Note).
• Conversely, for leukemia, Korea's 5-year relative survival rate is 55.7% while the SEER-based figure is 68.6%; the note explains that this is difficult to compare simply because the composition of leukemia cases (ratio of acute to chronic, age at diagnosis) differs between the two countries.

Why Do Outcomes Differ So Much by Cancer Type?

• Since national statistics vary greatly by cancer type, you should look at your specific cancer type rather than "cancer" as a whole.
• Based on Korean statistics (National Cancer Registration Statistics 2019–2023), the figures are 94.7% for breast cancer, 78.6% for stomach cancer, 75.6% for colorectal cancer, 40.4% for liver cancer, and 55.7% for leukemia, while the combined 5-year relative survival rate for all cancers over the same period is 73.7%.
• Liver cancer typically develops on top of chronic hepatitis or cirrhosis, so not only the cancer stage but also the liver function grade and portal pressure significantly determine the range of treatment options available.
• Blood cancers such as leukemia, lymphoma, and multiple myeloma have entirely different courses depending on subtype, so the overall "leukemia" figure cannot be directly applied to an individual case.

In What Order Is a Treatment Plan Finalized?

• Rather than a country's ranking, the actual treatment pathway matters, and it is finalized in the following order.
• Step 1: Upload imaging (DICOM), biopsy results, and medical certificates to request a remote review (pre-arrival review). A written opinion is issued within 5 business days from the date all records are complete.
• Step 2: The written opinion presents hospital comparisons and package estimates suited to the stage and conditions.
• Step 3: The actual treatment cost is finalized through an estimate issued by the hospital based on stage, surgical method, and length of hospital stay; the remote review fee of KRW 1,000,000 (about US$730) is deducted from the treatment cost if you proceed with treatment under contract.
• Step 4: Testing and treatment proceed, and upon returning home, a handover document noting the next test schedule and medications allows local medical staff to continue follow-up care.

FAQ — Should I Just Choose the Country with the Highest Cancer Survival Rate?

Survival rates are population averages, not numbers that predict an individual's outcome. National statistics such as National Cancer Registration Statistics or SEER are heavily influenced by screening systems and early detection rates, so your own stage, subtype, and biopsy results matter far more for determining actual treatment direction than a country's overall average.

FAQ — Can I Just Use Test Results From Another Country As They Are?

In most cases, they serve as reference material. However, for markers that determine drug selection — such as HER2, PD-L1, and genetic testing — testing methods and diagnostic criteria can differ between institutions, so if results are ambiguous, bringing paraffin blocks or slides allows for reconfirmation. If you upload imaging (DICOM), biopsy results, and medical certificates together during remote review, any additional tests needed will be noted in the written opinion.

Sources and Notes

• This article was written based on notes on stomach cancer, breast cancer, colorectal cancer, blood cancer, liver cancer, and insurance and documentation (National Cancer Information Center, National Cancer Center Korea, National Cancer Registration Statistics 2019–2023, NCCN Guidelines for Patients, SEER, Ministry of Health and Welfare).
• This content is provided for general medical information purposes only, and diagnosis, treatment methods, and outcomes may vary depending on individual conditions. Accurate diagnosis and treatment should always be determined through consultation with medical professionals.